Zepp Health (NYSE:ZEPP) Upgraded at Wall Street Zen

Key Points

• Wall Street Zen upgraded Zepp Health from “sell” to “hold,” while MarketBeat reports an overall consensus “Hold” rating and a $53.01 price target.
• Zepp Health shares opened at $5.02 and have traded between $3.85 and $61.85 over the past year, with a market capitalization of approximately $73.7 million.
• Institutional investors own 52.61% of the company, while insiders hold 36%; CFO Cheng Deng recently sold shares to cover tax withholding obligations related to vested equity awards.

Zepp Health (NYSE:ZEPP - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "sell" rating to a "hold" rating in a report released on Monday.

Separately, Fundamental Research set a $53.01 price target on shares of Zepp Health and gave the stock a "buy" rating in a research report on Tuesday, August 11th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $53.01.

Zepp Health Trading Down 0.4%

Zepp Health stock opened at $5.02 on Monday. The firm has a 50 day moving average of $5.06 and a 200 day moving average of $10.83. The firm has a market capitalization of $73.69 million, a price-to-earnings ratio of -1.99 and a beta of 1.86. Zepp Health has a 12-month low of $3.85 and a 12-month high of $61.85. The company has a current ratio of 0.88, a quick ratio of 0.67 and a debt-to-equity ratio of 0.21.

Insider Activity at Zepp Health

In other news, CFO Cheng Deng sold 9,836 shares of the company's stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $4.61, for a total value of $45,343.96. Following the completion of the transaction, the chief financial officer owned 114,539 shares of the company's stock, valued at $528,024.79. This represents a 7.91% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 36.00% of the stock is owned by insiders.

Institutional Trading of Zepp Health

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. FIL Ltd purchased a new position in Zepp Health during the 4th quarter valued at approximately $16,858,000. Millennium Management LLC bought a new stake in Zepp Health in the 3rd quarter worth approximately $11,265,000. UBS Group AG raised its holdings in shares of Zepp Health by 16,412.0% during the 3rd quarter. UBS Group AG now owns 181,302 shares of the company's stock worth $8,300,000 after acquiring an additional 180,204 shares in the last quarter. Monolith Management Ltd purchased a new stake in shares of Zepp Health during the 4th quarter worth approximately $3,601,000. Finally, State Street Corp bought a new position in shares of Zepp Health during the 4th quarter valued at approximately $3,421,000. Institutional investors own 52.61% of the company's stock.

Zepp Health Company Profile

Zepp Health Corp is a technology company specializing in the design, development and sale of smart wearable devices and health management solutions. Through its flagship Amazfit brand and the Zepp software ecosystem, the company offers a range of products—including smartwatches, fitness bands, smart scales and health-oriented mobile applications—designed to track key biometric data such as heart rate, sleep patterns, blood oxygen levels and activity metrics. Zepp Health's integrated platform enables users to monitor wellness and fitness goals while leveraging cloud-based analytics for personalized insights.

At the core of Zepp Health's offering is its Zepp cloud platform, which aggregates and analyzes data collected from its hardware lineup.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source